NCT06362148View on ClinicalTrials.gov

Circulating Tumor DNA in Peripheral T-cell Lymphomas

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Peripheral T-cell LymphomaNK/T-Cell Lymphoma
Interventions
DIAGNOSTIC_TEST

Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay

Blood sampling for circulating tumor DNA analysis at baseline, cycle 2 day 1, cycle 3 day 1, mid-treatment, end of induction/end of treatment, 100 day follow-up, 6 month, 12 month, 18 month and 24 month follow-up. Blood sampling will also be done in case of relapsing/refractory disease at any point prior to the abovementioned time points.

DIAGNOSTIC_TEST

18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)

FDG-PET/CT performed at baseline, mid-treatment, end of induction/end of treatment and 6 month, 12 month, 18 month and 24 month follow-up.

Trial Locations (1)

8200

RECRUITING

Department of Hematology, Aarhus University Hospital, Aarhus

All Listed Sponsors
collaborator

Aarhus University Hospital

OTHER

lead

University of Aarhus

OTHER